Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
31 Mai 2023 - 6:04PM
Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on
31 May 2023
REGULATED INFORMATION
COMBINED SHAREHOLDERS’ MEETING OF IPSEN
S.A.HELD ON 31 MAY 2023
ALL THE RESOLUTIONS SUBMITTED TO THE
SHAREHOLDERS’ VOTE HAVE BEEN APPROVED
Paris (France), 31 May
2023 – The Combined Shareholders’ Meeting of IPSEN S.A.
(Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel
des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France),
under the chairmanship of Mr. Marc de GARIDEL, Chairman of the
Board of Directors and meeting Chairman, and in the presence of the
members of the Board of Directors and the Group’s Executive
Leadership Team.
The Shareholders’ Meeting approved all of the 27
resolutions submitted by the Board of Directors and in particular
the payment of a dividend of €1.20 per share. This dividend will be
paid on 6 June 2023, the ex-date being 2 June 2023.
The Meeting also approved the renewal of the
appointment of KPMG S.A. as statutory auditor for a duration of six
financial years and the renewal of the terms of office of Mr. Marc
de GARIDEL, Mr. Henri BEAUFOUR and Mrs. Michèle OLLIER as
directors, for a duration of four years.
The articles of association of the Company have
been amended to raise the age limit applicable to the office of
Chairman of the Board of Directors to 75 years (article 16.1) and
to adopt a wording allowing to dematerialize the keeping of the
registers of the minutes of the Board of Directors (article
16.6).
During the Meeting, Mr. Marc de Garidel,
Chairman of the Board of Directors, commented on the information
concerning the governance and the activity of Ipsen's Board of
Directors and its committees during
FY 2022. Mr. David LOEW, Chief Executive Officer,
and Mr. Aymeric Le CHATELIER, Group Chief Financial Officer,
focused notably on the Group strategy, the 2022 financial
performance and the financial objectives for the year 2023.
Ipsen
Ipsen is a global, mid-sized biopharmaceutical
company focused on transformative medicines in Oncology, Rare
Disease and Neuroscience. With total sales of €3.0bn in FY 2022,
Ipsen sells medicines in over 100 countries. Alongside its
external-innovation strategy, the Company’s research and
development efforts are focused on its innovative and
differentiated technological platforms located in the heart of
leading biotechnological and life-science hubs: Paris-Saclay,
France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has
around 5,000 colleagues worldwide and is listed in Paris (Euronext:
IPN) and in the U.S. through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com.
Contacts
Investors |
|
Craig MarksVice President, Investor Relations+44
7584 349 193 |
Nicolas BoglerSenior Manager,
Investor Relations+33 (0) 6 52 19 98 92 |
Media |
|
Amy WolfVice President and Head of Corporate
BrandStrategy and Communications+41 79 576 07 23 |
Ioana PiscociuSenior
Manager, Global Media Relations+33 6 69 09 12 96 |
- Ipsen - Press release post SM - 31 May 2023
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024